Simvastatin Evokes An Unpredicted Antagonism For Tamoxifen In MCF-7 Breast Cancer Cells

References

• Siegel R, Miller K, Jemal A. Cancer statistics, 2018. Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor–positive breast cancer. Oncology. 2012;26(8):688–694.22957400
   PubMed Web of Science ®Google Scholar
• Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005;23(8):1736–1750. doi:10.1200/JCO.2005.11.05015755982
   PubMed Web of Science ®Google Scholar
• Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4- hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res. 2008;6:1630–1638. doi:10.1158/1541-7786.MCR-07-217218922978
   PubMed Web of Science ®Google Scholar
• Lagadec C, Adriaenssens E, Toillon RA, et al. Tamoxifen and trail synergistically induce apoptosis in breast cancer cells. Oncogene. 2008;27:1472–1477. doi:10.1038/sj.onc.121074917767197
   PubMed Web of Science ®Google Scholar
• Ali S, Rasool M, Chaoudhry H, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation. 2016;12(3):135. doi:10.6026/bioinformation28149048
   PubMed Web of Science ®Google Scholar
• Capasso I, Esposito E, Pentimalli F, et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: national Cancer Institute of Naples experience. Cancer Biol Ther. 2011;10:1240–1243.
   Web of Science ®Google Scholar
• Gérard C, Brown KA. Obesity and breast cancer - role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. Mol Cell Endocrinol. 2018;466:15–30. doi:10.1016/j.mce.2017.09.01428919302
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Gerber M, Decarli A, et al. HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol. 1993;22:772–780. doi:10.1093/ije/22.5.7728282454
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29:1592–1598. doi:10.1200/JCO.2010.31.520021422422
   PubMed Web of Science ®Google Scholar
• Cote-Daigneault J, Mehandru S, Ungaro R, Atreja A, Colombel JF. Potential immunomodulatory effects of statins in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:724–732. doi:10.1097/MIB.000000000000064026809008
   PubMed Web of Science ®Google Scholar
• Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Ind J Endocrinol Metabol. 2015;19:554–562. doi:10.4103/2230-8210.163106
   PubMedGoogle Scholar
• Van Wyhe RD, Rahal OM, Woodward WA. Effect of statins on breast cancer recurrence and mortality: a review. Breast Cancer Targets Ther. 2017;9:559–565.
   PubMed Web of Science ®Google Scholar
• Lacerda L, Reddy JP, Liu D, et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014;3:849–856. doi:10.5966/sctm.2013-020424833589
   PubMed Web of Science ®Google Scholar
• Jin Y, Xu K, Chen Q, et al. Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radio-sensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Exp Cell Res. 2018;362(2):362–369. doi:10.1016/j.yexcr.2017.11.03729208461
   PubMed Web of Science ®Google Scholar
• Li J, Liu J, Liang Z, et al. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell Death Dis. 2017;8(3):e2673. doi:10.1038/cddis.2017.46
   PubMedGoogle Scholar
• Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135:261–269. doi:10.1007/s10549-012-2154-x22806241
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton D, Lash TL, Ahern TP, et al. Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. Acta Oncol (Madr). 2018;57(1):120–128. doi:10.1080/0284186X.2017.1407040
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792–1802. doi:10.1056/NEJMoa120173523134381
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst. 1990;82:1107–1112. doi:10.1093/jnci/82.13.11072359136
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681. doi:10.1124/pr.58.3.1016968952
   PubMed Web of Science ®Google Scholar
• Buege AJ, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310.672633
   PubMedGoogle Scholar
• Ellman GL. Tissue sulfhydryl groups. Arch BiochemBiophys. 1959;82:70–77. doi:10.1016/0003-9861(59)90090-6
   PubMed Web of Science ®Google Scholar
• Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5:62–71. doi:10.1006/niox.2000.031911178938
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi:10.1016/0003-2697(76)90527-3942051
   PubMed Web of Science ®Google Scholar
• Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005;38:73–83. doi:10.2144/05381RV0115679089
   PubMed Web of Science ®Google Scholar
• Gjerde N, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2005;1082:6–14. doi:10.1016/j.chroma.2005.01.00416038189
   PubMed Web of Science ®Google Scholar
• Motawia TK, Abdelazima SA, Darwisha HA, Elbaza EM, Shouman SA. Could caffeic acid phenethylester expand the antitumor effect of tamoxifen in breast carcinoma? Nutr Cancer. 2016;68:435–445. doi:10.1080/01635581.2016.115366927007181
   PubMed Web of Science ®Google Scholar
• Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. PharmacolExpTher. 2011;336:496–505.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Silva DD, Alessi JV, Mano MS. Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. E Cancer Med Sci. 2016;10:609–623.
   Google Scholar
• Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S, Davydov M. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev. 2012;6(2):1–8. doi:10.4081/oncol.2012.e15
   Google Scholar
• Hwang JJ, Kim HN, Kim J, et al. Zinc (II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals. 2010;23:997–1013. doi:10.1007/s10534-010-9346-920524045
   PubMed Web of Science ®Google Scholar
• Bruning A, Friese K, Burges A, Mylonas I. Tamoxifen enhances the cytotoxic effect of nelfinavir in breast cancer cells. Breast Cancer Res. 2010;12:45–56. doi:10.1186/bcr2602
   Web of Science ®Google Scholar
• Yang S, Zhou Q, Yang X. Caspase −3 status is determinant of differential responses to genistein between MDA-MB-231and MCF-7 breast cancer cells. Biochim Biophys Acta. 2007;1773:903–911. doi:10.1016/j.bbamcr.2007.03.02117490757
   PubMed Web of Science ®Google Scholar
• Tait SW, Ichim G, Green DR. Die another way – non-apoptotic mechanisms of cell death. J Cell Sci. 2014;127:2135–2144. doi:10.1242/jcs.09357524833670
   PubMed Web of Science ®Google Scholar
• Mandal M, Kumar R. BcI-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells1. A A. 1996;100:10.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Rivenzon‐Segal D, Boldin‐Adamsky S, Seger D, Seger R, Degani H. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer. 2003;107(2):177–182. doi:10.1002/(ISSN)1097-021512949791
   PubMed Web of Science ®Google Scholar
• Hesselbarth N, Pettinelli C, Gericke M, et al. Tamoxifen affects glucose and lipid metabolism parameters, causes browning of subcutaneous adipose tissue and transient body composition changes in C57BL/6NTac mice. Biochem Biophys Res Commun. 2015;464:724–729. doi:10.1016/j.bbrc.2015.07.01526164229
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932–936. doi:10.1038/nature0447816355210
   PubMed Web of Science ®Google Scholar
• Johnson KE, Forward JA, Tippy MD, et al. Tamoxifen directly inhibits platelet angiogenicpotential and platelet-mediated metastasis. Arterioscler Thromb Vasc Biol. 2017;37:664–674. doi:10.1161/ATVBAHA.116.30879128153880
   PubMed Web of Science ®Google Scholar
• Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C. Estradiol increases VEGF in human breast studied by whole tissue culture. Cell Tissue Res. 2006;325:245–251. doi:10.1007/s00441-006-0159-716568303
   PubMed Web of Science ®Google Scholar
• Nilsson UW, Garvin S, Dabrosin C. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat. 2007;102:253–261. doi:10.1007/s10549-006-9335-417031577
   PubMed Web of Science ®Google Scholar
• Park MH, Hong JT. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 2016;5:1–15. doi:10.3390/cells5020015
   Web of Science ®Google Scholar
• Gopalan A, Yu W, Sanders BG, Kline K. Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett. 2013;329:9–16. doi:10.1016/j.canlet.2012.08.03122960596
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602–3609.1711413
   PubMed Web of Science ®Google Scholar
• Sanchez CA, Rodriguez E, Varela E, et al. Statin induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Investig. 2008;26:698–707. doi:10.1080/0735790070187465818608208
   PubMed Web of Science ®Google Scholar
• Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G. Simvastatin induces depression of PTEN expression via NFκB to inhibit breast cancer cell growth. Cell Signal. 2010;22:749–758. doi:10.1016/j.cellsig.2009.12.01020060890
   PubMed Web of Science ®Google Scholar
• Spampanato C, De Maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40:935–941. doi:10.3892/ijo.2011.127322134829
   PubMed Web of Science ®Google Scholar
• Taha DA, De Moor CH, Barrett DA, et al. The role of acid-base imbalance in statin-induced myotoxicity. Transl Res. 2016;174:140–160. doi:10.1016/j.trsl.2016.03.01527083388
   PubMed Web of Science ®Google Scholar
• Wang G, Cao R, Wang Y. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signaling pathway. Sci Rep. 2016;6:35783. doi:10.1038/srep3578327779188
   PubMed Web of Science ®Google Scholar
• Sohn HM, Hwang JY, Ryu JH, et al. Simvastatin protects ischemic spinal cord injury from cell death and cytotoxicity through decreasing oxidative stress: in vitro primary cultured rat spinal cord model under oxygen and glucose deprivation reoxygenation conditions. J OrthopSurg Res. 2017;12:36–44.
   Web of Science ®Google Scholar
• Kanugula AK, Kotamraju S. Statin-induced molecular mechanisms of breast cancer cell death: recent developments. Cancer Cell Microenviron. 2014;1:e390.
   Google Scholar
• Brewer TM, Masuda H, Liu DD, et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013;109:318–324. doi:10.1038/bjc.2013.34223820253
   PubMed Web of Science ®Google Scholar
• Nowis D, Malenda A, Furs K, et al. Statins impair glucose uptake in human cells. BMJ Open Diabetes Res Care. 2014;2:e000017. doi:10.1136/bmjdrc-2014-000017
   PubMedGoogle Scholar
• Malenda A, Skrobanska A, Issat T, et al. Statins impair glucose uptake in tumor cells. Neoplasia. 2012;14:311–323. doi:10.1593/neo.1244422577346
   PubMed Web of Science ®Google Scholar
• Coimbra M, Banciu M, Fens MH, et al. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J Control Release. 2010;148:303–310. doi:10.1016/j.jconrel.2010.09.01120869410
   PubMed Web of Science ®Google Scholar
• Shen Y, Du Y, Zhang Y, Pan Y. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Mol Med Rep. 2015;12(1):456–462. doi:10.3892/mmr.2015.340625738757
   PubMed Web of Science ®Google Scholar
• Buranrat B, Suwannaloet W, Naowaboot J. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncol Lett. 2017;14:6243–6250. doi:10.3892/ol.2017.678329113274
   PubMed Web of Science ®Google Scholar
• Abdoul-Azize S, Buquet C, Li H, Picquenot JM, Vannier JP. Integration of Ca2+ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. Oncogene. 2018;37(36):4979–4982. doi:10.1038/s41388-018-0329-629795329
   PubMed Web of Science ®Google Scholar
• Liang Z, Li W, Liu J, et al. Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells. Sci Rep. 2017;7:41776–41786. doi:10.1038/srep4177628150753
   PubMed Web of Science ®Google Scholar
• Shaitelman SF, Stauder MC, Allen P, et al. Impact of statin use on outcomes in triple negative breast cancer. J Cancer. 2017;8:2026–2032. doi:10.7150/jca.1874328819403
   PubMed Web of Science ®Google Scholar
• Göbel A, Breining D, Rauner M, Hofbauer LC, Rachner TD. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death Dis. 2019;10(2):91. doi:10.1038/s41419-019-1322-x30692522
   PubMedGoogle Scholar
• Armengol S, Arretxe E, Enzunza L, et al. SREBP-2-driven transcriptional activation of human SND1 oncogene. Oncotarget. 2017;8(64):108181. doi:10.18632/oncotarget.v8i6429296233
   PubMedGoogle Scholar
• Arretxe E, Armengol S, Mula S, Chico Y, Ochoa B, Martinez MJ. Profiling of promoter occupancy by the SND1 transcriptional coactivator identifies downstream glycerolipid metabolic genes involved in TNF alpha response in human hepatoma cells. Nucleic Acids Res. 2015;43:10673–10688. doi:10.1093/nar/gkv85826323317
   PubMed Web of Science ®Google Scholar
• Ma H, Yao Y, Wang C, et al. Transcription factor activity of estrogen receptor α activation upon nonylphenol or bisphenol A treatment enhances the in vitro proliferation, invasion, and migration of neuroblastoma cells. Onco Targets Ther. 2016;9:3451.27366082
   PubMed Web of Science ®Google Scholar
• Li X, Song QS, Wang JY, et al. Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERα expression and uterine wet weight in ovariectomized rats. J Bone Miner Metab. 2011;29(4):396–403. doi:10.1007/s00774-010-0231-y21063740
   PubMed Web of Science ®Google Scholar
• Du Meng ML, Han Y, Zhao D, Zhang X, Yang Y, Liu R. MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. Onco Targets Ther. 2018;11:7733. doi:10.2147/OTT.S18722130464522
   PubMed Web of Science ®Google Scholar
• Klein G, Vellenga E, Fraaije MW, Kamps WA, Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004;50:87–100. doi:10.1016/j.critrevonc.2003.09.00115157658
   PubMed Web of Science ®Google Scholar
• Thunyakitpisal PD, Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004;94:403–409. doi:10.1254/jphs.94.40315107580
   PubMed Web of Science ®Google Scholar
• Kang S, Kim ES, Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009;21:1317–1322. doi:10.3892/or_0000035719360310
   PubMed Web of Science ®Google Scholar
• Chen YJ, Chang LS. Simvastatin induces NF kB/p65 down-regulation and JNK1/c-Jun/ATF- 2 activation leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Biochem Pharmacol. 2014;92:530–543. doi:10.1016/j.bcp.2014.09.02625316568
   PubMed Web of Science ®Google Scholar